FDA Has Recalled Thousands of Bottles of Antidepressant Duloxetine, Sold Under Brand Name ...
The Duloxetine Delayed-Release Capsules' voluntary recall began on Oct. 10 after the FDA deemed the medication the ...
She was in pain for years, but doctors had no answers. A rare condition was to blame.
Jill Becher spent more than three years in agonizing pain. After one surgery failed, a riskier treatment provided relief.
Verywell Health on MSN2 天
Over 7,000 Bottles of Antidepressant Recalled Over Cancer Risk
The recall covers more than 7,000 bottles of duloxtine, sold as Cymbalta, due to the presence of nitrosamines.
Rolling Out1 天
7 incredible breakthroughs in acupuncture revolutionizing sciatica treatment
Groundbreaking research has transformed our understanding of acupuncture's role in treating sciatica, a debilitating ...
Impacts13 天
From Pain to Relief: Understanding the Root Causes and Effective Cures
Pain is a universal experience—one that can range from mild discomfort to debilitating agony. Whether it’s chronic back pain, ...
phillyvoice.com10 天
Physical therapy can address the root causes of chronic pain
In 2020, an estimated 54 million adults in the U.S. were living with chronic pain. Over 25 percent of them were treating ...
Thousands of bottles of common antidepressant Cymbalta recalled by FDA over cancer-causing ...
Thousands of bottles of a commonly prescribed antidepressant drug were recalled because they contained a suspected cancer-causing chemical.
Medscape1 小时
FDA Announces Recall of More than 7000 Bottles of Duloxetine
The nationwide recall of more than 7000 bottles of duloxetine delayed-release capsules is due to unacceptable levels of a ...
Duloxetine Antidepressant Recall Update As FDA Sets Risk Class
On October 11, the recall was classified as a class II recall by the FDA—a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health ...
Antidepressant recall: FDA upgrades medication risk class to 2nd highest level in recall update
The U.S. Food and Drug Administration is urging patients not to stop taking their prescribed medication if it falls under the ...
ophthalmologytimes9 天
AAO 2024: Long-term low-dose antiviral treatment benefits patients with eye disease and ...
New research presented at the American Academy of Ophthalmology’s Cornea Subspecialty Day is part of the part of the 8-year ...
Black patients less likely to receive certain pain relief post-surgery, new research suggests
Although a combination of certain pain medications has been found to be more effective than opioids alone at managing ...